RESUMEN
Wearable cuffless photoplethysmographic blood pressure monitors have garnered widespread attention in recent years; however, the long-term performance values of these devices are questionable. Most cuffless blood pressure monitors require initial baseline calibration and regular recalibrations with a cuffed blood pressure monitor to ensure accurate blood pressure estimation, and their estimation accuracy may vary over time if left uncalibrated. Therefore, this study assessed the accuracy and long-term performance of an upper-arm, cuffless photoplethysmographic blood pressure monitor according to the ISO 81060-2 standard. This device was based on a nonlinear machine-learning model architecture with a fine-tuning optimized method. The blood pressure measurement protocol followed a validation procedure according to the standard, with an additional four weekly blood pressure measurements over a 1-month period, to assess the long-term performance values of the upper-arm, cuffless photoplethysmographic blood pressure monitor. The results showed that the photoplethysmographic signals obtained from the upper arm had better qualities when compared with those measured from the wrist. When compared with the cuffed blood pressure monitor, the means ± standard deviations of the difference in BP at week 1 (baseline) were -1.36 ± 7.24 and -2.11 ± 5.71 mmHg for systolic and diastolic blood pressure, respectively, which met the first criterion of ≤5 ± ≤8.0 mmHg and met the second criterion of a systolic blood pressure ≤ 6.89 mmHg and a diastolic blood pressure ≤ 6.84 mmHg. The differences in the uncalibrated blood pressure values between the test and reference blood pressure monitors measured from week 2 to week 5 remained stable and met both criteria 1 and 2 of the ISO 81060-2 standard. The upper-arm, cuffless photoplethysmographic blood pressure monitor in this study generated high-quality photoplethysmographic signals with satisfactory accuracy at both initial calibration and 1-month follow-ups. This device could be a convenient and practical tool to continuously measure blood pressure over long periods of time.
Asunto(s)
Determinación de la Presión Sanguínea , Muñeca , Presión Sanguínea/fisiología , Calibración , Determinación de la Presión Sanguínea/métodos , Monitoreo FisiológicoRESUMEN
Rapid eye movement (REM) sleep behavior disorder (RBD) is associated with Parkinson's disease (PD). In this study, a smartwatch-based sensor is utilized as a convenient tool to detect the abnormal RBD phenomenon in PD patients. Instead, a questionnaire with sleep quality assessment and sleep physiological indices, such as sleep stage, activity level, and heart rate, were measured in the smartwatch sensors. Therefore, this device can record comprehensive sleep physiological data, offering several advantages such as ubiquity, long-term monitoring, and wearable convenience. In addition, it can provide the clinical doctor with sufficient information on the patient's sleeping patterns with individualized treatment. In this study, a three-stage sleep staging method (i.e., comprising sleep/awake detection, sleep-stage detection, and REM-stage detection) based on an accelerometer and heart-rate data is implemented using machine learning (ML) techniques. The ML-based algorithms used here for sleep/awake detection, sleep-stage detection, and REM-stage detection were a Cole-Kripke algorithm, a stepwise clustering algorithm, and a k-means clustering algorithm with predefined criteria, respectively. The sleep staging method was validated in a clinical trial. The results showed a statistically significant difference in the percentage of abnormal REM between the control group (1.6 ± 1.3; n = 18) and the PD group (3.8 ± 5.0; n = 20) (p = 0.04). The percentage of deep sleep stage in our results presented a significant difference between the control group (38.1 ± 24.3; n = 18) and PD group (22.0 ± 15.0, n = 20) (p = 0.011) as well. Further, our results suggested that the smartwatch-based sensor was able to detect the difference of an abnormal REM percentage in the control group (1.6 ± 1.3; n = 18), PD patient with clonazepam (2.0 ± 1.7; n = 10), and without clonazepam (5.7 ± 7.1; n = 10) (p = 0.007). Our results confirmed the effectiveness of our sensor in investigating the sleep stage in PD patients. The sensor also successfully determined the effect of clonazepam on reducing abnormal REM in PD patients. In conclusion, our smartwatch sensor is a convenient and effective tool for sleep quantification analysis in PD patients.
Asunto(s)
Clonazepam/farmacología , Enfermedad de Parkinson , Trastorno de la Conducta del Sueño REM , Algoritmos , Humanos , Enfermedad de Parkinson/diagnóstico , Trastorno de la Conducta del Sueño REM/complicaciones , Trastorno de la Conducta del Sueño REM/diagnóstico , SueñoRESUMEN
RATIONALE: Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune disease that is associated with cell-surface NMDAR-targeting autoantibodies. Typical anti-NMDAR encephalitis symptoms include psychosis, seizure and extrapyramidal side effects. However, early diagnosis of anti-NMDAR encephalitis remains challenging due to the complexity of the motor phenomenon. PATIENT CONCERNS: Here, we report a new diagnosis of anti-NMDAR encephalitis in a young woman with a history of epilepsy. DIAGNOSES: Electroencephalography revealed a typical "extreme delta brush" pattern, which indicated anti-NMDAR encephalitis. INTERVENTIONS: The clinical status of the patient markedly improved after immediate and aggressive immunosuppression therapies. OUTCOMES: The patient was discharged with mild cognitive impairment. However, this was completely resolved 1 month postdischarge. LESSONS: We conclude that subacute onset focal seizure with psychosis as well as compatible electroencephalography findings (i.e., extreme delta brush patterns) should be considered notable early indicators of anti-NMDAR encephalitis. This would ensure early and effective clinical interventions, which are essential for favorable outcomes.
Asunto(s)
Encefalitis Antirreceptor N-Metil-D-Aspartato/fisiopatología , Electroencefalografía/métodos , Encefalitis Antirreceptor N-Metil-D-Aspartato/diagnóstico , Femenino , Humanos , Convulsiones/diagnóstico , Convulsiones/fisiopatología , Adulto JovenRESUMEN
BACKGROUND: Dystonia is a common feature in spinocerebellar ataxias (SCAs). Whether the presence of dystonia is associated with different rate of ataxia progression is not known. OBJECTIVES: To study clinical characteristics and ataxia progression in SCAs with and without dystonia. METHODS: We studied 334 participants with SCA 1, 2, 3 and 6 from the Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) and compared the clinical characteristics of SCAs with and without dystonia. We repeatedly measured ataxia progression by the Scale for Assessment and Rating of Ataxia every 6 months for 2 years. Regression models were employed to study the association between dystonia and ataxia progression after adjusting for age, sex and pathological CAG repeats. We used logistic regression to analyze the impact of different repeat expansion genes on dystonia in SCAs. RESULTS: Dystonia was most commonly observed in SCA3, followed by SCA2, SCA1, and SCA6. Dystonia was associated with longer CAG repeats in SCA3. The CAG repeat number in TBP normal alleles appeared to modify the presence of dystonia in SCA1. The presence of dystonia was associated with higher SARA scores in SCA1, 2, and 3. Although relatively rare in SCA6, the presence of dystonia was associated with slower progression of ataxia. CONCLUSIONS: The presence of dystonia is associated with greater severity of ataxia in SCA1, 2, and 3, but predictive of a slower progression in SCA6. Complex genetic interactions among repeat expansion genes can lead to diverse clinical symptoms and progression in SCAs.
Asunto(s)
Progresión de la Enfermedad , Distonía/etiología , Ataxias Espinocerebelosas/complicaciones , Ataxias Espinocerebelosas/genética , Adulto , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Blefaroptosis/complicaciones , Blefaroptosis/diagnóstico , Limitación de la Movilidad , Blefaroptosis/diagnóstico por imagen , Blefaroptosis/genética , ADN Polimerasa gamma/genética , Diagnóstico Diferencial , Humanos , Masculino , Persona de Mediana Edad , Debilidad Muscular/complicaciones , Debilidad Muscular/diagnóstico , Debilidad Muscular/diagnóstico por imagen , Debilidad Muscular/genética , Mutación , Trastornos Parkinsonianos/complicaciones , Trastornos Parkinsonianos/genéticaRESUMEN
BACKGROUND: ß-Thalassemia major patients with higher total drug levels [deferasirox (DEFR) plus its iron complex] do not yield better serum ferritin (SF) control. This study aimed to determine the concentrations of DEFR and its iron complex (Fe-[DEFR]2) in thalassemia patients to predict the chelation efficacy in terms of SF and cardiac T2* values. METHODS: Patients' steady-state drug levels at trough (Ctrough) and 2 hours postdose (C2h) were determined. Because iron deposition may cause changes in the hepatic metabolism of amino acids, the concentrations of 40 amino acids in plasma were also assayed at 2 hours postdose. RESULTS: A total of 28 patients either dosing daily or twice daily were recruited. After a 1-month DEFR maintenance therapy, 38.8% and 30% of patients from groups of once-daily and twice-daily, respectively, had a plasma DEFR-iron complex formation ratio higher than 0.05 [High Chelation Ratio, (HCR)]. After a 6-month follow-up, those patients who had a HCR (n = 10) at C2h showed more favorable median changes in SF and cardiac T2* values (-388.0, +10.1) than those with a low DEFR-iron complex formation ratio (Low Chelation Ratio; n = 18; +10.5; +4.5) compared with the baseline. The levels of plasma L-arginine, L-alanine, L-glycine, L-norleucine, and L-serine were significantly lower in patients with the low Chelation Ratio condition than the levels in HCR patients. CONCLUSIONS: This therapeutic drug monitoring study revealed that a DEFR-iron complex formation ratio at C2h might be an applicable indicator of the efficacy of long-term DEFR iron chelation therapy. A better iron-control response to DEFR was observed in the patients with HCRs. The trends for the ratio might have value in dose-setting and need to be validated in a larger cohort.
Asunto(s)
Benzoatos/administración & dosificación , Benzoatos/sangre , Quelantes del Hierro/administración & dosificación , Hierro/sangre , Triazoles/administración & dosificación , Triazoles/sangre , Talasemia beta/sangre , Talasemia beta/tratamiento farmacológico , Adolescente , Adulto , Aminoácidos/sangre , Benzoatos/farmacocinética , Deferasirox , Monitoreo de Drogas/métodos , Femenino , Humanos , Quelantes del Hierro/farmacocinética , Hígado/metabolismo , Masculino , Triazoles/farmacocinética , Adulto JovenRESUMEN
The aim of this study is to determine whether the initial symptom associates with motor progression in spinocerebellar ataxias (SCAs). SCAs are clinically heterogeneous and the initial presentation may represent different subtypes of SCA with different motor progression. We studied 317 participants with SCAs1, 2, 3, and 6 from the Clinical Research Consortium for SCAs (CRC-SCA) and repeatedly measured the severity of ataxia for 2 years. SCA patients were divided into gait-onset and non-gait-onset (speech, vision, and hand dexterity) groups based on the initial presentation. In addition to demographic comparison, we employed regression models to study ataxia progression in these two groups after adjusting for age, sex, and pathological CAG repeats. The majority of SCA patients had gait abnormality as an initial presentation. The pathological CAG repeat expansions were similar between the gait-onset and non-gait-onset groups. In SCA1, gait-onset group progressed slower than non-gait-onset group, while gait-onset SCA6 group progressed faster than their counterpart. In addition, the disease presented 9 years later for SCA2 gait-onset group than non-gait-onset group. Initial symptoms of SCA3 did not influence age of onset or disease progression. The initial symptom in each SCA has a different influence on age of onset and motor progression. Therefore, gait and non-gait-onset groups of SCAs might represent different subtypes of the diseases.
Asunto(s)
Ataxinas/genética , Ataxia Cerebelosa/genética , Ataxias Espinocerebelosas/genética , Adulto , Anciano , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proteínas Represoras/genética , Ataxias Espinocerebelosas/diagnóstico , Repeticiones de Trinucleótidos/genéticaAsunto(s)
Encefalopatías Metabólicas/tratamiento farmacológico , Hemosiderina/efectos de los fármacos , Hemosiderosis/tratamiento farmacológico , Quelantes del Hierro/farmacología , Piridonas/farmacología , Encefalopatías Metabólicas/diagnóstico por imagen , Encefalopatías Metabólicas/fisiopatología , Deferiprona , Femenino , Hemosiderosis/diagnóstico por imagen , Hemosiderosis/fisiopatología , Humanos , Quelantes del Hierro/administración & dosificación , Persona de Mediana Edad , Piridonas/administración & dosificaciónRESUMEN
PURPOSE: Deferasirox (DEFR), when administered BID, improves iron overload and decreases DEFR-related adverse effects in patients with ß-thalassemia major. However, the pharmacokinetic (PK) disposition of DEFR and the iron-DEFR complex (Fe-[DEFR]2) in this dosing strategy is unclear. METHODS: Chromatographic analysis was performed using a solvent delivery system coupled to an HPLC-UV detector to determine the steady-state concentrations of DEFR (CDEFR) and Fe-(DEFR)2 (CFe-[DEFR]2) in ß-thalassemia major patients (n = 8) following either once-daily or BID dosing, during which the PK parameters of the 2 dosing schedules were compared. FINDINGS: An HPLC-UV system for the analysis of blood samples following solid-phase extraction was validated. Patients who received 40 mg/kg of DEFR had higher mean CDEFR and CFe-[DEFR]2 values at all sampling times. However, concentrations of iron-DEFR complex were similar in patients who received 30 or 40 mg/kg of DEFR in the once-daily group at the 6- to 24-hour sampling times. There was no significant difference in any of the PK parameters; however, DEFR administration BID increased the mean trough levels of DEFR (183.8 [157.5] µmol/L) compared with once daily (87.7 [56.8] µmol/L), whereas all the patients had increased peak levels per individual DEFR dose when they were switched from once daily to BID (139.0 [59.8] µmol/L vs 289.2 [145.8] µmol/L, respectively). IMPLICATIONS: Splitting the dose increased the peak levels of DEFR per unit dose in all patients and tends to increase drug exposures, but there were no significant differences in DEFR PK parameter estimates. Switching from once daily to BID may be considered for patients with an inadequate response to chelation therapy to achieve optimal drug levels. Further research is needed with a larger sample size to determine the clinical importance of the significant results due to the interindividual variability of DEFR.
Asunto(s)
Benzoatos/sangre , Quelantes del Hierro/farmacocinética , Hierro/sangre , Triazoles/sangre , Talasemia beta/sangre , Adulto , Benzoatos/administración & dosificación , Benzoatos/uso terapéutico , Cromatografía Líquida de Alta Presión/métodos , Deferasirox , Esquema de Medicación , Femenino , Humanos , Hierro/administración & dosificación , Hierro/uso terapéutico , Quelantes del Hierro/administración & dosificación , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/sangre , Sobrecarga de Hierro/tratamiento farmacológico , Masculino , Triazoles/administración & dosificación , Triazoles/uso terapéutico , Adulto Joven , Talasemia beta/tratamiento farmacológicoRESUMEN
Human-worn rehabilitation exoskeletons have the potential to make therapeutic exercises increasingly accessible to disabled individuals while reducing the cost and labor involved in rehabilitation therapy. In this work, we propose a novel human-model-in-the-loop framework for virtual prototyping (design, control and experimentation) of rehabilitation exoskeletons by merging computational musculoskeletal analysis with simulation-based design techniques. The framework allows to iteratively optimize design and control algorithm of an exoskeleton using simulation. We introduce biomechanical, morphological, and controller measures to quantify the performance of the device for optimization study. Furthermore, the framework allows one to carry out virtual experiments for testing specific "what-if" scenarios to quantify device performance and recovery progress. To illustrate the application of the framework, we present a case study wherein the design and analysis of an index-finger exoskeleton is carried out using the proposed framework.
Asunto(s)
Dedos/fisiología , Músculo Esquelético/fisiología , Robótica/instrumentación , Personas con Discapacidad/rehabilitación , Humanos , Modelos Teóricos , Rehabilitación/instrumentación , Robótica/métodosRESUMEN
The passive stiffness at the MCP joint is a result of the elasticity of muscle-tendon units (MTUs) and capsule ligament complex (CLC), however, the relative contributions of these two components are unknown. We hypothesize that the MTUs provide the majority of the contributions to the joint stiffness by generating resistive forces when the MCP joint is flexed or extended. We used the work done by passive moments as a measure for the determination of the contributions to the joint stiffness. We conducted experiments with ten human subjects and collected joint angle and finger tip force data. The total passive moment and joint angle data were fitted with a double exponential model, and the passive moments due to the MTUs were determined by developing subject-specific models of the passive force-length change relationships. Our results show that for all the subjects, the work done by the passive moments from the MTUs is less than 50% of the total work done, and the CLC provides dominant contributions to the joint stiffness throughout the flexion-extension range of the joint angle. Therefore, the hypothesis that the MTUs provide the majority of the contributions to the MCP joint stiffness is not supported. We also determined that the majority of the MTUs passive moment was generated by the extrinsic MTUs and the contributions of the intrinsic MTUs was negligible.
Asunto(s)
Articulación Metacarpofalángica/fisiología , Músculo Esquelético/fisiología , Rango del Movimiento Articular/fisiología , Tendones/fisiología , Adulto , Femenino , Dedos , Humanos , Masculino , Modelos Biológicos , Adulto JovenRESUMEN
BACKGROUND: In this study, the authors studied the effect of thioridazine (TDZ) on the pharmacokinetic profile of quetiapine (QTP) in Taiwanese patients with schizophrenia. METHODS: Sixteen subjects with schizophrenia were recruited for this study. The authors pretreated 8 patients with TDZ 50 mg daily continuously given until the end of the study. QTP was administered to all the participants, and their doses were escalated to 300 mg once daily over a 7-day period and maintained for another week. On day 15, blood samples were collected at 12 time points within an 8-hour interval. The authors assayed the plasma levels of QTP with a high-performance liquid chromatography system coupled with ultraviolet detector. RESULTS: Significantly decreased plasma levels of QTP after oral administration were observed in patients comedicated with TDZ compared with the QTP monotherapy group at 1.5, 2, and 2.5 hours, and the P values were 0.046, 0.001, and 0.005, respectively. The Cmax of QTP was significantly lower in the group comedicated with TDZ (776.9 ± 175.2 versus 1452.3 ± 707.5 ng/mL; P = 0.002). The oral clearance of QTP was significantly higher in the combined group than in the monothreapy group (123.3 ± 66.8 versus 60.3 ± 28.5 L/h; P = 0.03). Other pharmacokinetic parameters were not significantly different. CONCLUSIONS: The coadministration of TDZ significantly decreased plasma QTP level and significantly increased the oral clearance of QTP. Although TDZ is switched to QTP, choosing larger doses of QTP for titration may be necessary to avoid the emergence of psychotic symptoms among schizophrenic patients.